NASDAQ:KALA - Nasdaq - US4831192020 - Common Stock - Currency: USD
NASDAQ:KALA (2/21/2025, 8:00:02 PM)
6.64
-0.2 (-2.92%)
The current stock price of KALA is 6.64 USD. In the past month the price decreased by -18.53%. In the past year, price decreased by -5.95%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
KALA BIO, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 43 full-time employees. The company went IPO on 2017-07-20. The firm is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its KPI-012 is used for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The firm is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
KALA BIO INC
1167 Massachusetts Avenue
Arlington MASSACHUSETTS 02472 US
CEO: Mark Iwicki
Employees: 43
Company Website: https://www.kalarx.com/
Investor Relations: https://investors.kalarx.com/
Phone: 17819965252
The current stock price of KALA is 6.64 USD. The price decreased by -2.92% in the last trading session.
The exchange symbol of KALA BIO INC is KALA and it is listed on the Nasdaq exchange.
KALA stock is listed on the Nasdaq exchange.
8 analysts have analysed KALA and the average price target is 15.3 USD. This implies a price increase of 130.42% is expected in the next year compared to the current price of 6.64. Check the KALA BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
KALA BIO INC (KALA) has a market capitalization of 40.44M USD. This makes KALA a Nano Cap stock.
KALA BIO INC (KALA) currently has 43 employees.
KALA BIO INC (KALA) has a support level at 6.39 and a resistance level at 6.64. Check the full technical report for a detailed analysis of KALA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
KALA does not pay a dividend.
KALA BIO INC (KALA) will report earnings on 2025-03-27, after the market close.
KALA BIO INC (KALA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.46).
The outstanding short interest for KALA BIO INC (KALA) is 2.82% of its float. Check the ownership tab for more information on the KALA short interest.
ChartMill assigns a fundamental rating of 1 / 10 to KALA. KALA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months KALA reported a non-GAAP Earnings per Share(EPS) of -12.46. The EPS increased by 45.18% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -62.84% | ||
ROE | -282.23% | ||
Debt/Equity | 1.66 |
ChartMill assigns a Buy % Consensus number of 85% to KALA. The Buy consensus is the average rating of analysts ratings from 8 analysts.